The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Chimerix turns $39m into $935m
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Zepzelca’s pivotal surprise
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Phase 1 entrants seek improved safety
First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.
